April 07, 2006

Theragenetics for Schizophrenia Diagnostics

IP2IPO Group PLC, the intellectual property commercialisation company, said it has invested 390,000 stg for a 48 pct stake in Theragenetics Ltd, a pharmacogenetic diagnostics spin-out company from the Institute of Psychiatry, King's College London (UK).

Theragenetics said it will develop and commercialise pharmacogenetic diagnostic tests to help guide and improve the treatment of schizophrenia and other disorders

Commenting on today's announcement, Alan Aubrey, IP2IPO's Chief Executive, said: 'We believe that the high reputation enjoyed by the Institute of Psychiatry at King's is well justified and are very pleased to be establishing what will be our first spin-out company from the School. Theragenetics is addressing a large and important market and we consider that it has the potential to make a
significant impact.'

Alison Campbell, Managing Director of King's College London Enterprises, said:
'Through the formation of Theragenetics we are able to bring together basic and clinical research and accelerate its development for direct patient benefit.' Professor Rob Kerwin, one of the academic founders of Theragenetics, said: 'This is a good example of translational medicine. It is very exciting to have established Theragenetics to develop our research findings into clinical utility.'

For more information:
IP2IPO is an intellectual property (IP) company that specialises in
commercialising university technology. www.ip2ipo.com


Post a comment

Please enter this code to enable your comment -
Remember Me?
(you may use HTML tags for style)
* indicates required